Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
TitleA Comparison of SUMOylation in HK1 and BL41 Cell Lines
AbstractNearly 96% of the population is infected with Epstein Barr virus (EBV), a gammaherpesvirus that results in a life-long infection. EBV lytically infects B lymphocytes and epithelial cells, and it establishes latency in B lymphocytes. Latent EBV infection often evades the host’s immune system; however, the presence of the EBV genome in certain cancers suggests that the virus is associated with approximately 200,000 new cases of cancer, specifically Burkitt’s lymphoma, Hodgkin’s lymphoma (HL), and nasopharyngeal carcinoma (NPC), each year. One cellular process commonly dysregulated in cancers, including EBV-positive lymphomas, is the post-translational modification of lysine residues by the Small Ubiquitin-like Modifier (SUMO), and SUMOylation inhibitors have been proposed to have potential anti-cancer properties. Our recent work focused on the small molecule inhibitor ML-792, which decreases global levels of SUMOylated proteins in EBV-positive and EBV-negative B lymphocytes. Similar experiments repeated with paired EBV-negative and EBV-positive nasopharyngeal cell line HK1 revealed that ML-792 only inhibited SUMOylation processes in the EBV-positive epithelial cells and not in their EBV-negative counterparts. We hypothesized that EBV may differentially modulate SUMOylation processes in epithelial cells when compared with B lymphocytes. This study aims to elaborate on the role of EBV on SUMOylation in epithelial cells. Paired primary B lymphocytes and epithelial cells were examined to determine the expression of the SUMO machinery. Results showed that EBV infection coincided with increased levels of SUMO-modified proteins and the SUMO-activating enzyme (SAE1 and SAE2), but not the SUMO-conjugating enzyme (Ubc9). Global levels of SUMOylated proteins increased in EBV-positive HK1 cells when compared with their EBV-negative counterparts. However, RNA and protein levels of the SUMO machinery varied greatly, which led us to ask if the confluence of the epithelial cells affected EBV-mediated changes in cells. Results demonstrated that RNA levels of the SUMO machinery significantly increased in sub-confluent EBV-positive HK1 cells, but these changes were not as apparent at the protein level. EBV-medicated changes in the SUMO machinery were more apparent at the protein level in confluent cells. To mimic a more physiological environment, EBV-negative and EBV-positive HK1 cells were also grown using a modified air-liquid interface method to model the human airway. Results showed that the presence of EBV corresponded with increased levels of the SUMO-activating enzyme and the SUMO-conjugating enzyme. Furthermore, the pattern of SUMOylated proteins changed in EBV-positive cells when compared with their EBV-negative counterparts. Taken together, our findings demonstrate that EBV does manipulate the SUMO machinery in epithelial cells, but not to the same extent as it does in lymphocytes. Therefore, additional studies are needed to better understand the effect of EBV on global levels of SUMOylated proteins in epithelial cells, which could identify if SUMOylation inhibitors have a therapeutic potential in the treatment of EBV-positive epithelial cancers.